

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 1

PATENT NO. : 6,818,229
APPLICATION NO.: 08/962,027
ISSUE DATE : Nov. 16, 2004
INVENTOR(S) : Eugenio A. Cefali and David J. Bova

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At claim 1, column 28, line 62: please delete the phrase "nictoinic" and replace it with the phrase "nicotinic"
At claim 3, column 29, line 3: please delete the phrase "realse" and replace it with the phrase "release"
At claim 3, column 29, line 9: please delete the phrase "nictoinuric" and replace it with the phrase "nicotinuric"
At claim 4, column 29, line 11: please delete the phrase "clain 3" and replace it with the phrase "claim 3"
At claim 5, column 29, line 16: please delete the phrase "fomlation" and replace it with the phrase "fomulation"
At claim 5, column 29, line 23: please delete the phrase "nictoinic" and replace it with the phrase "nicotinic"
At claim 9, column 29, line 36: please delete the phrase "containig" and replace it with the phrase "containing"
At claim 9, column 29, line 36: please delete the phrase "between" and replace it with the phrase "between"
At claim 13, column 29, line 54: please delete the phrase "asministration" and replace it with the phrase "administration"
At claim 13, column 29, line 56: please delete the phrase "formlation" and replace it with the phrase "formulation"
At claim 13, column 29, line 63: please delete the phrase "nictoinic" and replace it with the phrase "nicotinic"
At claim 18, column 30, line 18: please delete the phrase "nocotinic" and replace it with the phrase "nicotinic"
At claim 21, column 30, line 25: please delete the phrase "nicotrinic" and replace it with the phrase "nicotinic"
At claim 21, column 30, lines 30- 31: please delete the phrase "containg at least about 100 mg" and insert the phrase "containing at least about 1000 mg"
At claim 21, column 30, line 36: please delete the phrase "nictoinic" and replace it with the phrase "nicotinic"
At claim 24, column 30, line 45: please delete the phrase "formuation" and replace it with the phrase "formulation"
At claim 25, column 30, line : please delete the phrase "niotinuric" and replace it with the phrase "nicotinuric"

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Claim

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: D.L. Stassi, et al.

Patent No.: 6,818,291

Issue Date: Nov. 16, 2004

Serial No.: 08/962,027

Filed: October 31, 1997

For: INTERMEDIATE RELEASE
NICOTINIC ACID
COMPOSITIONS FOR TREATING
HYPERLIPIDEMIA

Date: March 1, 2009

Certificate of Electronic Filing:

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being electronically filed with U.S. Patent and Trademark Office on:

Date of Deposit: March 1, 2009

/Rachel A. Polster/

Rachel A. Polster

REQUEST FOR CERTIFICATE OF CORRECTION

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Upon review of the final printed copies of the above-identified patent, Applicants have identified typographical errors in the patent as printed. Accordingly Applicants request that a Certificate of Correction be issued pursuant to 35 U.S.C. 254 for this patent as set forth on the attached Form PTO PTO/SB/44, identifying errors by column and line from the patent.

Some of these errors appear to be due to the fault of the Applicant, except that:

Claim 3: there was no error in the phrase "release" as originally filed;

Claim 4: there was no error in the phrase "claim 3" as originally filed;

Claim 5: there was no error in the phrase "formulation" as originally filed;

Claim 9: there was no error in the phrases "containing" or " between" as originally filed;

Claim 13: there was no error in the phrases "administration" or "formulation" as originally filed;

Claim 18: there was no error in the phrase "nicotinic" as originally filed;

Claim 21: there was no error in the phrase "nicotinic" as originally filed in line 25;

Claim 21: there was no error in the phrase "containing at least about 1000 mg" as originally filed.

Claim 24: there was no error in the phrase "formulation" as originally filed.

Claim 25: there was no error in the phrase "nicotinuric" as originally filed.

Authorization is given to charge deposit account number 01-0025 for the fee set forth in §1.20(a).

ABBOTT LABORATORIES

Customer Number 23492

Telephone: (847) 937-0107le123
Facsimile: (847) 938-2623

Respectfully submitted,
Cefali, et al.

/Rachel A. Polster 47, 004/
Rachel Polster
Registration No. 47,004
Attorney for Applicants